Providing multiple options through a single solution

Ventripoint Diagnostics Ltd. (TSX.V: VPT) is one of this year’s Venture 50 companies — the company has developed the first cost effective and accurate tool for measuring the function of all four chambers of the heart, with accuracy equivalent to MRI, but through the convenience of 2D Ultrasound.

VentriPoint Diagnostics is a medical device company. It is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease.

The 2018 Venture 50 is a ranking of top performers on the TSX Venture Exchange over the last year. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.

For the full 2018 Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50

This story was provided by Market One Media Group for commercial purposes.